Skip to main content Back to Top
Advertisement

11/20/2019

Dorzolamide 2% and Timolol 0.5% Ophthalmic Solution

Products Affected - Description

    • Cosopt ophthalmic solution, Akorn, 22.3 mg-6.8 mg/mL, 10 mL Ocumeter Plus bottle, 1 count, NDC 17478-0605-10
    • Dorzolamide and Timolol ophthalmic solution, Bausch Health, 22.3 mg-6.8 mg/mL, 10 mL bottle, 1 count, NDC 24208-0486-10

Reason for the Shortage

    • Akorn has dorzolamide and timolol ophthalmic solution on shortage due to manufacturing delays.
    • Sandoz did not provide a reason for the shortage.
    • Teva discontinued dorzolamide and timolol ophthalmic solution in April 2018.
    • Bausch Health had dorzolamide and timolol ophthalmic solution on shortage due to manufacturing delays.

Available Products

    • Cosopt PF ophthalmic solution, Akorn, 22.3 mg-6.8 mg/mL, 0.2 mL single-use preservative-free vial, 60 count, NDC 17478-0604-30
    • Dorzolamide and Timolol ophthalmic solution, Akorn, 22.3 mg-6.8 mg/mL, 10 mL bottle, 1 count, NDC 50383-0233-10
    • Dorzolamide and Timolol ophthalmic solution, Sandoz, 22.3 mg-6.8 mg/mL, 10 mL bottle, 1 count, NDC 61314-0030-02

Estimated Resupply Dates

    • Akorn has Cosopt 2%/0.5% ophthalmic solution in 10 mL bottles on back order and the company estimates a release date of 1st quarter 2020.
    • Bausch Health has dorzolamide/timolol 2%/0.5% ophthalmic solution in 10 mL bottles on back order and the company estimates a release date of mid-December 2019.

Implications for Patient Care

    • Each product contains dorzolamide hydrochloride 22.3 mg/mL (equivalent to dorzolamide 2%) and timolol maleate 6.8 mg/mL (equivalent to timolol 0.5%).

Updated

Updated November 20, 2019 by Rachael Freeman, PharmD, BCPS. Created October 30, 2017 by Benjamin Witt, PharmD, BCPS, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins